Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.62 |
| ▸ | KDR | P35968 | 13/20 | 0.62 |
| ▸ | IGF1R | P08069 | 9/20 | 0.62 |
| ▸ | INSR | P06213 | 3/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.62 |
| ▸ | KIT | P10721 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | PRKACA | P17612 | 1/20 | 0.62 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.62 |
| ▸ | JAK1 | P23458 | 1/20 | 0.62 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.62 |
| ▸ | AKT1 | P31749 | 1/20 | 0.62 |
| ▸ | AKT2 | P31751 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963566 | 0.95 | MET (0.59) | METKDRIGF1RINSRAURKA | |
| SCHEMBL1963489 | 0.92 | MET (0.60) | METKDRIGF1RINSRAURKA | |
| SCHEMBL1963353 | 0.89 | MET (0.65) | METKDRIGF1RINSRAURKA | |
| SCHEMBL1963396 | 0.89 | MET (0.67) | METKDRIGF1RINSRAURKA | |
| SCHEMBL12474069 | 0.89 | MET (0.68) | METKDRIGF1RINSRAURKA | |
| SCHEMBL1963142 | 0.89 | MET (0.64) | METKDRIGF1RINSRAURKA | |
| SCHEMBL12474026 | 0.88 | MET (0.65) | METKDRIGF1RINSRAURKA | |
| SCHEMBL1964209 | 0.86 | MET (0.61) | METKDRIGF1RINSRAURKA | |
| SCHEMBL1966517 | 0.86 | MET (0.66) | METKDRIGF1RINSRAURKA | |
| SCHEMBL12474621 | 0.85 | MET (0.61) | METKDRIGF1RINSRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | claimed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | claimed |
| EP-2336123-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | Neopharm Co., Ltd. (KR) | 2011-06-22 | — | — | EP | claimed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | disclosed |
| WO-2010044543-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | 주식회사 네오팜 (KR) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | MET, HGFAC, DMPK | MET 1/4885KDR 181/4885IGF1R 310/4885 |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | MET, HGFAC, DMPK | MET 1/4885KDR 181/4885IGF1R 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.